Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis

Nature

Volumn 444, Issue 7122, 2006, Pages 1083-1087

  Ridgway, John ^a   Zhang, Gu ^a   Wu, Yan ^b   Stawicki, Scott ^b   Liang, Wei Ching ^b   Chanthery, Yvan ^a   Kowalski, Joe ^a   Watts, Ryan J ^a   Callahan, Christopher ^c   Kasman, Ian ^c   Singh, Mallika ^d   Chien, May ^d   Tan, Christine ^b   Hongo, Jo Anne S ^b   De Sauvage, Fred ^d   Plowman, Greg ^a   Yan, Minhong ^a  

^a Tumor Biology and Angiogenesis   (United States)

^b Antibody Engineering   (United States)

^c Pathology   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY YW152F; DLL4 ANTIBODY; NOTCH RECEPTOR; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIBODY; INHIBITION; SIGNALING; TUMOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; CELL SPECIFICITY; COLON CANCER; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 33845907380     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05313     Document Type: Article

References (22)

1. Duarte, A. et al. Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev. 18, 2474-2478 (2004).
2. Krebs, L. T. et al. Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev. 18, 2469-2473 (2004).
3. Gale, N. W. et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc. Natl Acad. Sci. USA 101, 15949-15954 (2004).
4. van Es, J. H. et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959-963 (2005).
5. Fre, S. et al. Notch signals control the fate of immature progenitor cells in the intestine. Nature 435, 964-968 (2005).
6. Patel, N. S. et al. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 65, 8690-8697 (2005).
7. Lee, C. V. et al. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J. Mol. Biol. 340, 1073-1093 (2004).
8. Liang, W. C. et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281, 951-961 (2006).
9. Nakatsu, M. N. et al. Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc. Res. 66, 102-112 (2003).
10. Baron, M. An overview of the Notch signalling pathway. Semin. Cell Dev. Biol. 14, 113-119 (2003).
11. Milano, J. et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci. 82, 341-358 (2004).
12. Williams, C. K., Li, J. L., Murga, M., Harris, A. L. & Tosato, G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107, 931-939 (2006).
13. Stone, J. & Dreher, Z. Relationship between astrocytes, ganglion cells and vasculature of the retina. J. Comp. Neurol. 255, 35-49 (1987).
14. Gerhardt, H. et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161, 1163-1177 (2003).
15. Fruttiger, M. Development of the mouse retinal vasculature: angiogenesis versus vasculogenesis. Invest. Ophthalmol. Vis. Sci. 43, 522-527 (2002).
16. Claxton, S. & Fruttiger, M. Periodic Delta-like 4 expression in developing retinal arteries. Gene Expr. Patterns 5, 123-127 (2004).
17. Ferrara, N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 94, 209-231 (2005).
18. Coultas, L., Chawengsaksophak, K. & Rossant, J. Endothelial cells and VEGF in vascular development. Nature 438, 937-945 (2005).
19. Lawson, N. D. et al. Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development 128, 3675-3683 (2001).
20. Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967-974 (2005).
21. Jain, R. K., Duda, D. G., Clark, J. W. & Loeffler, J. S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clin. Pract. Oncol. 3, 24-40 (2006).
22. Wong, G. T. et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279, 12876-12882 (2004).